Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof
The present invention relates to the crystalline forms of a 5-HT 1F receptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the present invention have advantages in crystallinity, hygroscopicity, morphology, crystal form stability, and chemical stability as compared with the known forms of lasmiditan and lasmiditan hydrochloride. The present invention also relates to processes for the preparation of the crystalline forms of lasmiditan and lasmiditan hydrochloride, pharmaceutical compositions thereof and their use in treating and/or preventing a patient's migraine and other diseases or conditions associated with 5-HT 1F receptor dysfunction.
1. Lasmiditan Form 1 having the structure shown in formula (I) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the lasmiditan Form 1, expressed as 2θ angles, has the following characteristic peaks: 5.3±0.2°, 12.5±0.2°, 13.3±0.2°, 15.2±0.2°, 16.6±0.2° and 19.8±0.2°.
2. The lasmiditan Form 1 according to claim 1 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 1, expressed as 2θ angles, has the following characteristic peaks: 5.0±0.2°, 5.3±0.2°, 7.2±0.2°, 10.1±0.2°, 12.5±0.2°, 13.3±0.2°, 14.9±0.2°, 15.2±0.2°, 16.6±0.2°, 19.8±0.2°, 21.7±0.2° and 22.4±0.2°.
3. The lasmiditan Form 1 according to claim 2 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 1, expressed as 2θ angles, has the following characteristic peaks and relative intensity:
Relative intensity %
2θ
(I)
5.0 ± 0.2°
50.0
5.3 ± 0.2°
96.2
7.2 ± 0.2°
37.4
10.1 ± 0.2°
52.9
10.7 ± 0.2°
31.7
12.5 ± 0.2°
62.0
13.3 ± 0.2°
81.1
14.9 ± 0.2°
77.3
15.2 ± 0.2°
89.5
15.9 ± 0.2°
46.2
16.6 ± 0.2°
100.0
18.6 ± 0.2°
39.9
19.8 ± 0.2°
59.7
21.7 ± 0.2°
26.1
22.4 ± 0.2°
60.5
22.8 ± 0.2°
46.2
24.0 ± 0.2°
49.4
24.5 ± 0.2°
29.0
25.5 ± 0.2°
41.2.
4. A method of preparing the lasmiditan Form 1 according to claim 1 , comprising any one of the following methods:
1) dissolving lasmiditan free base in a mixed solvent to form a solution, volatilizing the solution to dryness to obtain the lasmiditan Form 1; the mixed solvent is a mixture of water and a water-miscible organic solvent; wherein:
the mixed solvent is a water-methanol mixture, water-acetone mixture or water-acetonitrile mixture;
the mass to volume ratio of lasmiditan to the mixed solvent is from 50 to 500 mg: 1 mL;
the volume percentage of water in the mixed solvent is from 1% to 10%; and
the volatilization is carried out at room temperature;
2) forming a suspension of lasmiditan free base in a solvent, stirring for crystallization, separating the crystals, and then drying to obtain the lasmiditan Form 1; the solvent is selected from solvents containing water; wherein:
the solvent is water, a mixed solvent of ethanol and water, a mixed solvent of tetrahydrofuran and water or ethyl acetate saturated with water;
the volume percentage of water in the solvent is from 1% to 100%;
the mass to volume ratio of lasmiditan to the solvent is from 10 to 1000 mg: 1 mL;
the stirring time is from 0.5 hours to 3 days; and
the stirring is carried out at room temperature.
5. Lasmiditan Form 2 having the structure shown in formula (I) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the lasmiditan Form 2, expressed as 2θ angles, has the following characteristic peaks: 4.9±0.2°, 9.0±0.2°, 9.8±0.2°, 13.5±0.2°, 15.8±0.2° and 17.7±0.2°.
6. The lasmiditan Form 2 according to claim 5 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 2, expressed as 2θ angles, has the following characteristic peaks: 4.9±0.2°, 9.0±0.2°, 9.8±0.2°, 12.9±0.2°, 13.5±0.2°, 15.8±0.2°, 17.7±0.2°, 18.5±0.2°, 19.7±0.2°, 22.2±0.2°, 22.7±0.2° and 23.7±0.2°.
7. The lasmiditan Form 2 according to claim 6 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 2, expressed as 2θ angles, has the following characteristic peaks the relative intensity:
Relative intensity %
2θ
(I)
4.9 ± 0.2°
60.9
9.0 ± 0.2°
44.5
9.8 ± 0.2°
49.7
12.9 ± 0.2°
27.7
13.5 ± 0.2°
100.0
14.9 ± 0.2°
20.8
15.8 ± 0.2°
77.1
17.7 ± 0.2°
87.8
18.2 ± 0.2°
37.9
18.5 ± 0.2°
69.2
19.3 ± 0.2°
18.7
19.7 ± 0.2°
59.9
20.5 ± 0.2°
34.7
21.7 ± 0.2°
31.0
22.2 ± 0.2°
55.5
22.7 ± 0.2°
51.7
23.3 ± 0.2°
24.6
23.7 ± 0.2°
52.4
25.2 ± 0.2°
28.1
26.8 ± 0.2°
18.8.
8. A method of preparing the lasmiditan Form 2 according to claim 5 , comprising the steps as below: forming a suspension of lasmiditan free base in a solvent, then stirring for crystallization, separating the crystals, and drying to obtain the lasmiditan Form 2; wherein:
the solvent is selected from the group consisting of C 4 to C 6 ether, C 3 to C 5 ketone, C 1 to C 4 alcohol, C 2 to C 6 ester, and C 6 to C 8 alkane;
the mass to volume ratio of lasmiditan to the solvent is 10 to 1000 mg: 1 mL;
the stirring time is 1 to 7 days; and
the stirring is carried out at room temperature.
9. Lasmiditan Form 3 having the structure shown in formula (I) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the Form 3, expressed as 2θ angles, has the following characteristic peaks: 3.8±0.2°, 9.8±0.2°, 11.2±0.2°, 14.6±0.2°, 16.1±0.2° and 18.5±0.2°.
10. The lasmiditan Form 3 according to claim 9 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 3, expressed as 2θ angles, has the following characteristic peaks: 11.2±0.2°, 14.6±0.2°, 16.1±0.2°, 17.8±0.2°, 18.5±0.2°, 19.6±0.2°, 20.7±0.2°, 22.3±0.2°, 23.9±0.2° and 24.5±0.2°.
11. The lasmiditan Form 3 according to claim 10 , wherein the X-ray powder diffraction pattern of the lasmiditan Form 3, expressed as 2θ angles, has the following characteristic peaks and their relative intensity:
Relative intensity %
2θ
(I)
3.8 ± 0.2°
100.0
5.0 ± 0.2°
5.3
7.5 ± 0.2°
4.0
9.8 ± 0.2°
10.2
11.2 ± 0.2°
15.4
12.8 ± 0.2°
4.6
13.6 ± 0.2°
4.4
14.6 ± 0.2°
12.4
16.1 ± 0.2°
26.0
17.1 ± 0.2°
4.9
17.8 ± 0.2°
9.2
18.5 ± 0.2°
23.0
18.9 ± 0.2°
5.1
19.6 ± 0.2°
11.6
20.7 ± 0.2°
6.6
21.6 ± 0.2°
5.5
22.3 ± 0.2°
13.3
23.0 ± 0.2°
8.5
23.9 ± 9.2°
8.7
24.5 ± 9.2°
16.5.
12. A method of preparing the lasmiditan Form 3 according to claim 9 , comprising any one of the following methods:
1) dissolving lasmiditan free base in a solvent to form a solution, then adding 1 to 10% (wt %) of polyethylene glycol 4000, applying ultrasound to facilitate dissolution, and volatilizing to dryness to obtain the lasmiditan Form 3; wherein:
the solvent is a C 1 to C 4 alcohol;
the mass ratio of lasmiditan to solvent is 50 to 100 mg: 1 mL; and
the volatilization process is carried out at 40° C.;
2) dissolving lasmiditan free base in a solvent to form a solution, and volatilizing to dryness to obtain the lasmiditan Form 3; wherein:
the solvent is selected from the group consisting of isopropyl ether, isopropyl acetate and toluene;
the mass to volume ratio of lasmiditan to the solvent is 2 to 50 mg: 1 mL; and
the volatilization process is carried out at room temperature.
13. Lasmiditan hydrochloride Form A having the structure shown in formula (II) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the Form A, expressed as 2θ angles, has the following characteristic peaks: 12.1±0.2°, 13.1±0.2°, 15.8±0.2°, 18.9±0.2°, 19.8±0.2° and 25.3±0.2°.
14. The lasmiditan hydrochloride Form A according to claim 13 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form A, expressed as 2θ angles, has the following characteristic peaks: 9.3±0.2°, 12.1±0.2°, 13.1±0.2°, 15.8±0.2°, 18.9±0.2°, 19.8±0.2°, 21.0±0.2°, 22.0±0.2°, 23.5±0.2°, 25.3±0.2°, 27.3±0.2° and 27.6±0.2°.
15. The lasmiditan hydrochloride Form A according to claim 14 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form A, expressed as 2θ angles, has the following characteristic peaks and their relative intensity:
Relative intensity %
2θ
(I)
9.3 ± 0.2°
1.9
12.1 ± 0.2°
3.3
13.1 ± 0.2°
11.3
15.8 ± 0.2°
2.0
18.9 ± 0.2°
100.0
19.8 ± 0.2°
2.6
20.8 ± 0.2°
2.5
21.0 ± 0.2°
3.4
22.0 ± 0.2°
1.9
23.5 ± 0.2°
5.8
25.3 ± 0.2°
11.7
25.8 ± 0.2°
3.2
27.3 ± 0.2°
3.6
27.6 ± 0.2°
5.1.
16. A method of preparing the lasmiditan hydrochloride Form A according to claim 13 , comprising any one of the following methods:
1) dissolving lasmiditan hydrochloride in a solvent to form a solution, and volatilizing to dryness to obtain the lasmiditan hydrochloride Form A; wherein:
the solvent is selected from the group consisting of alcohol, nitromethane, dichloromethane, 1,4-dioxane, acetonitrile and a mixture thereof;
the mass to volume ratio of lasmiditan hydrochloride to solvent is 5 to 25 mg: 1 mL; and
the volatilization process is carried out at room temperature;
2) placing lasmiditan hydrochloride in a solvent to form a suspension, stirring for crystallization, separating the crystals, and drying to obtain the lasmiditan hydrochloride Form A; wherein:
the solvent is selected from the group consisting of alcohol, ether, ester, ketone, alkane, tetrahydrofuran, 1,4-dioxane, toluene and a mixture thereof;
the mass ratio of the lasmiditan hydrochloride to the solvent is 50 to 200 mg: 1 mL;
the stirring time is from 1 day to 7 days and the stirring process is carried out at room temperature.
17. Lasmiditan hydrochloride Form B having the structure shown in formula (III) below,
wherein the lasmiditan hydrochloride Form B is a dihydrate, and wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form B, expressed as 2θ angles, has the following characteristic peaks: 14.3±0.2°, 15.6±0.2°, 23.8±0.2°, 29.5±0.2°.
18. The lasmiditan hydrochloride Form B according to claim 17 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form B, expressed as 2θ angles, has the following characteristic peaks: 14.3±0.2°, 15.6±0.2°, 18.7±0.2°, 19.3±0.2°, 21.9±0.2°, 23.8±0.2°, 26.0±0.2°, 28.3±0.2°, 29.5±0.2°, 31.4±0.2°, 32.8±0.2° and 38.2±0.2°.
19. The lasmiditan hydrochloride Form B according to claim 18 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form B, expressed as 2θ angles, has the following characteristic peaks and their relative intensity:
Relative intensity %
2θ
(I)
14.3 ± 0.2°
100.0
15.6 ± 0.2°
76.1
17.0 ± 0.2°
7.0
18.7 ± 0.2°
20.1
19.3 ± 0.2°
19.9
21.7 ± 0.2°
8.0
21.9 ± 0.2°
10.7
23.8 ± 0.2°
70.1
24.4 ± 0.2°
12.7
26.0 ± 0.2°
27.3
27.7 ± 0.2°
6.3
28.3 ± 0.2°
10.5
29.0 ± 0.2°
10.9
29.5 ± 0.2°
54.3
30.3 ± 0.2°
12.3
31.4 ± 0.2°
17.9
32.8 ± 0.2°
36.4
38.2 ± 0.2°
44.9.
20. A method of preparing the lasmiditan hydrochloride Form B according to claim 17 , comprising any one of the following methods:
1) dissolving lasmiditan hydrochloride in a solvent to form a solution, cooling for crystallization, separating the crystalline form and drying to obtain the lasmiditan hydrochloride Form B; wherein:
the solvent is a mixed solvent containing water;
the volume percentage of water in the mixed solvent is 40% to 100%;
the mass to volume ratio of lasmiditan hydrochloride to the solvent is 100 to 200 mg: 1 mL;
the crystallization time is 3 to 5 days, the crystallization temperature is lower than the temperature of forming the solution;
the drying temperature is from 10° C. to 40° C.; and
the drying time is from 1 to 12 hours;
2) dissolving lasmiditan hydrochloride in a solvent to form a solution, and volatilizing to dryness to obtain the lasmiditan hydrochloride Form B; wherein:
the solvent is a mixed solvent containing water;
the volume percentage of water in the mixed solvent is 40% to 100%;
the mass to volume ratio of lasmiditan hydrochloride to the solvent is 100 to 150 mg: 1 mL; and
the volatilization process is carried out at room temperature.
21. Lasmiditan hydrochloride Form C having the structure shown in formula (IV) below,
wherein the lasmiditan hydrochloride Form C is a monohydrate, and wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form C, expressed as 2θ angles, has the following characteristic peaks: 13.1±0.2°, 13.8±0.2°, 14.9±0.2°, 16.6±0.2°, 18.0±0.2° and 22.2±0.2°.
22. The lasmiditan hydrochloride Form C according to claim 21 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form C, expressed as 2θ angles, has the following characteristic peaks: 13.1±0.2°, 13.8±0.2°, 14.9±0.2°, 16.6±0.2°, 17.7±0.2°, 18.0±0.2°, 19.6±0.2°, 20.4±0.2°, 21.6±0.2°, 22.2±0.2°, 24.6±0.2° and 27.5±0.2°.
23. The lasmiditan hydrochloride Form C according to claim 22 , wherein the X-ray powder diffraction pattern of the lasmiditan hydrochloride Form C, expressed as 2θ angles, has the following characteristic peaks and their relative intensity:
Relative intensity %
2θ
(I)
8.9 ± 0.2°
5.0
13.1 ± 0.2°
40.4
13.8 ± 0.2°
45.8
14.9 ± 0.2°
11.5
16.6 ± 0.2°
100.0
17.0 ± 0.2°
5.6
17.7 ± 0.2°
13.8
18.0 ± 0.2°
33.2
19.1 ± 0.2°
4.3
19.6 ± 0.2°
11.6
20.4 ± 0.2°
8.4
21.6 ± 0.2°
11.7
22.2 ± 0.2°
32.9
24.6 ± 0.2°
7.7
25.9 ± 0.2°
9.9
26.7 ± 0.2°
5.9
27.5 ± 0.2°
12.7
28.3 ± 0.2°
11
29.1 ± 0.2°
5.2
31.1 ± 0.2°
7.1.
24. A method of preparing the lasmiditan hydrochloride Form C according to claim 21 , comprising any one of the following methods:
1) dissolving lasmiditan hydrochloride in a solvent to form a solution, and volatilizing to dryness to obtain the lasmiditan hydrochloride Form C; wherein:
the solvent is selected from the group consisting of a mixed solvent of trifluoroethanol and water, a mixed solvent of isopropyl alcohol and water, water-saturated n-butanol, and water-saturated 2-butanol;
the volume percentage of water in the mixed solvent is 2% to 10%;
the mass to volume ratio of lasmiditan hydrochloride to the solvent is 10 to 50 mg:
1 mL; and
the volatilization process is carried out at room temperature;
2) dissolving lasmiditan hydrochloride in a solvent to form a solution, cooling the solution for crystallization, separating the crystals and drying to obtain the lasmiditan hydrochloride Form C; wherein:
the solvent is a mixed solvent of water and acetone;
the volume percentage of water in the mixed solvent is 2% to 5%;
the mass ratio of lasmiditan hydrochloride to the solvent is 25 to 50 mg: 1 mL;
the crystallization time is 1 to 7 days;
the crystallization temperature is lower than the temperature of forming the solution;
the drying temperature is from 10° C. to 40° C.; and
the drying time is from 1 to 12 hours.
25. A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the lasmiditan Form 1 according to claim 1 , and at least one pharmaceutically acceptable carrier.
26. A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the lasmiditan Form 2 according to claim 5 , and at least one pharmaceutically acceptable carrier.
27. A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the lasmiditan Form A according to claim 13 , and at least one pharmaceutically acceptable carrier.
28. A pharmaceutical composition comprising a therapeutically and/or preventively effective amount of the lasmiditan Form C according to claim 21 , and at least one pharmaceutically acceptable carrier.